NCT06946381 (CAMPARI) is a clinical trial of Evar in Aortoiliac Aneurysm, sponsored by Federico II University.

Who is sponsoring NCT06946381?

NCT06946381 is sponsored by Federico II University.

What drugs are being tested in NCT06946381?

Interventions in NCT06946381: Evar.

What condition does NCT06946381 study?

NCT06946381 studies Aortoiliac Aneurysm, Iliac Aneurysm.

Is NCT06946381 still recruiting?

NCT06946381 is currently recruiting now. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT06946381: CAMPARI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAMpania PugliA bRanch Iliaco

Recruiting now Last updated 27 April 2025

What this trial tests

trial testing Evar in Aortoiliac Aneurysm in 200 participants. Currently enrolling.

Timeline

1 January 2015

Primary endpoint
1 January 2026

1 January 2028

Quick facts

Lead sponsor	Federico II University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 January 2015
Primary completion	1 January 2026
Estimated completion	1 January 2028
Sites	2 locations across Italy

Drugs / interventions tested

Evar

Conditions studied

Aortoiliac Aneurysm — all drugs for Aortoiliac Aneurysm →
Iliac Aneurysm — all drugs for Iliac Aneurysm →

Sponsor

Federico II University

Who can join

Eligibility, any sex, with Aortoiliac Aneurysm or Iliac Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Spontaneus Multicentric Observational registry to investigate the medium and long-term performances of the Iliac E-liac Branch Device from Artivion for treatment of Aortoiliac aneurysms in a real-world consecutive patients cohort.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mid-Term Results of the Multicenter CAMPARI Registry Using the E-Liac Iliac Branch Device for Aorto-Iliac Aneurysms.
Noce F, Accarino G, Angiletta D, Guercio LD, et al · · 2026 · PMID 41590875 · DOI 10.3390/jcdd13010048

Verify or expand the search:

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06946381 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06946381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing